Citadel Advisors’s Wave Life Sciences WVE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16M Buy
2,202,856
+1,412,892
+179% +$18.4M ﹤0.01% 2611
2025
Q4
$13.4M Buy
+789,964
New +$8.03M ﹤0.01% 2854
2025
Q3
Sell
-32,405
Closed -$262K 14282
2025
Q2
$211K Sell
32,405
-29,551
-48% -$195K ﹤0.01% 10564
2025
Q1
$501K Buy
61,956
+58,738
+1,825% +$642K ﹤0.01% 8473
2024
Q4
$39.8K Sell
3,218
-934,368
-100% -$12.5M ﹤0.01% 12615
2024
Q3
$7.69M Buy
937,586
+912,870
+3,693% +$5.46M ﹤0.01% 3296
2024
Q2
$123K Sell
24,716
-59,913
-71% -$342K ﹤0.01% 10625
2024
Q1
$522K Sell
84,629
-1,897,623
-96% -$9.5M ﹤0.01% 8299
2023
Q4
$10M Buy
+1,982,252
New +$10.6M ﹤0.01% 2842
2023
Q3
Sell
-3,110
Closed -$11.3K 15230
2023
Q2
$11.3K Sell
3,110
-81,443
-96% -$329K ﹤0.01% 13149
2023
Q1
$366K Sell
84,553
-13,985
-14% -$64.1K ﹤0.01% 8966
2022
Q4
$690K Buy
+98,538
New +$454K ﹤0.01% 7569
2022
Q2
Sell
-21,305
Closed -$41K 14242
2022
Q1
$43K Buy
21,305
+6,067
+40% +$14.9K ﹤0.01% 12900
2021
Q4
$48K Sell
15,238
-35,210
-70% -$146K ﹤0.01% 13274
2021
Q3
$247K Buy
+50,448
New +$306K ﹤0.01% 11507
2021
Q2
Sell
-18,618
Closed -$122K 14542
2021
Q1
$104K Sell
18,618
-28,532
-61% -$274K ﹤0.01% 12442
2020
Q4
$371K Sell
47,150
-611,441
-93% -$5.13M ﹤0.01% 8700
2020
Q3
$5.59M Buy
+658,591
New +$7.22M ﹤0.01% 2999
2020
Q2
Sell
-26,124
Closed -$246K 10605
2020
Q1
$245K Sell
26,124
-34,280
-57% -$292K ﹤0.01% 7670
2019
Q4
$484K Sell
60,404
-13,838
-19% -$339K ﹤0.01% 6852
2019
Q3
$1.52M Buy
74,242
+17,122
+30% +$393K ﹤0.01% 4900
2019
Q2
$1.49M Sell
57,120
-22,954
-29% -$644K ﹤0.01% 5031
2019
Q1
$3.11M Sell
80,074
-146,525
-65% -$5.95M ﹤0.01% 3695
2018
Q4
$9.53M Buy
+226,599
New +$10.1M 0.01% 1947
2018
Q2
Sell
-11,204
Closed -$449K 9355
2018
Q1
$449K Buy
+11,204
New +$471K ﹤0.01% 6078

Other funds holding WVE

Citadel Advisors's WVE Position: Q1 2026 in Review

Citadel Advisors increased its Wave Life Sciences (WVE) stake by 179% in Q1 2026, buying an estimated $18.4M and bringing the position to 2,202,856 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Citadel Advisors first reported a position in WVE in Q1 2018 and has held it in 25 quarters since. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Citadel Advisors held 2,202,856 shares of Wave Life Sciences worth $16M as of Q1 2026.
  • Citadel Advisors bought 1,412,892 Wave Life Sciences shares in Q1 2026, an estimated $18.4M.
  • Wave Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2611 holding.
  • Citadel Advisors first reported a position in Wave Life Sciences in Q1 2018 and has held it in 25 quarters since.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.